<DOC>
	<DOCNO>NCT00303745</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , irinotecan capecitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . It yet know whether irinotecan capecitabine effective irinotecan alone treat colorectal cancer . PURPOSE : This randomized phase II trial study irinotecan capecitabine see well work second-line therapy compare irinotecan alone treat old patient progressive , metastatic colorectal cancer remove surgery .</brief_summary>
	<brief_title>Irinotecan With Without Capecitabine Second-Line Therapy Treating Older Patients With Progressive , Metastatic Colorectal Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare objective response stable disease rate elderly patient unresectable , progressive , metastatic colorectal cancer treat irinotecan hydrochloride v without capecitabine . Secondary - Compare tolerability regimens patient . - Compare quality life ability maintain self-sufficiency patient treat regimen . - Compare progression-free overall survival patient treat regimen . OUTLINE : This open-label , randomize , multicenter study . Patients stratify accord participate center , WHO performance status ( 0 1 v 2 ) , number associate comorbidities ( Charlson index 0-2 v &gt; 2 ) , age ( 75-79 v ≥ 80 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive irinotecan hydrochloride IV 90 minute day 1 . Treatment repeat every 2 week 2 course absence disease progression unacceptable toxicity . - Arm II : Patients receive oral capecitabine day 1-14 irinotecan hydrochloride IV 90 minute day 1 . Treatment repeat every 3 week 2 course absence disease progression unacceptable toxicity . Quality life assess baseline every 12 week thereafter . After completion study therapy , patient follow every 12 week . PROJECTED ACCRUAL : A total 78 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic adenocarcinoma colon rectum Unresectable disease Documented progressive disease firstline/palliative chemotherapy Measurable disease ≥ 1 cm outside prior radiation field No brain metastasis PATIENT CHARACTERISTICS : WHO performance status 02 Life expectancy ≥ 3 month No contraindication chemotherapy Creatinine clearance ≥ 40 mL/min Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Alkaline phosphatase ≤ 3 time normal ( 5 time normal hepatic involvement ) Bilirubin ≤ 1.5 time normal Transaminases ≤ 5 time normal No symptomatic coronary disease cardiac insufficiency No enteropathy chronic diarrhea No unresolved intestinal occlusion subocclusion No history severe unexpected reaction fluoropyrimidine No active malignancy past 2 year No hypersensitivity irinotecan hydrochloride excipients No hypersensitivity capecitabine fluorouracil PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior extensive resection No concurrent sorivudine similar analog ( e.g. , brivudine ) No concurrent anticancer therapy Concurrent radiotherapy allow nontarget lesion</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>